NWRN — Newron Pharmaceuticals SpA Share News
0.000.00%
Last trade - 00:00- CH₣174.16m
- CH₣182.76m
- €19.13m
Brief: Newron Completes Patient Enrollment In Pivotal STARS Study
Brief: Newron Pharmaceuticals: Commercialization Partner Zambon With Valeo Pharma Announce Approval Of Onstryv® (Safinamide) For Parkinson’S Disease In Canada
Brief: Newron Pharmaceuticals: Zambon Announces Approval And ARTG Listing Of Safinamide In Australia
Brief: Newron Pharmaceuticals H1 Net Loss Of EUR 7.6 Mln
Corrected: Swiss stocks - Factors to watch on Sept 13
Brief: Newron Pharmaceuticals Provides Update On STARS Clinical Study With Sarizotan For Treatment Of Rett Syndrome
Swiss stocks - Factors to watch on March 1
Brief: Newron Pharmaceuticals FY Net Loss Narrows To EUR 5.28 Million
Swiss stocks - Factors to watch on Feb 9
Brief: Newron Pharmaceuticals: Current Cash Position At Approx EUR 60 Mln
Brief: Newron raises CHF 27.0 mln in a private placement of new shares
Swiss stocks - Factors to watch on Sept 26
Brief: Newron launches a private placement of new shares
Brief: Newron Pharmaceuticals H1 net result swings to profit of EUR 1.5 mln
Brief: Newron Pharmaceuticals: Xadago available in U.S. for Parkinson's disease patients
Brief: Newron Pharmaceuticals receives 11.3 million euros milestone payments for US approval of Xadago
Brief: Newron Pharmaceuticals: Valeo Pharma and Zambon form partnership for Parkinson's disease treatment Xadago in Canada
Brief: Newron Pharmaceuticals: XADAGO to be introduced in Portugal
Swiss stocks - Factors to watch on March 22